Margate, FLNCT07711002Now EnrollingIRB Ready

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Clinical Trial in Margate, FL

Access cutting-edge metastatic hormone-sensitive prostate cancer (mhspc) treatment through this phase 3 clinical trial at a research site in Margate. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Margate location

Preparing your pre-screening questions…

Expert Care in Margate

Access metastatic hormone-sensitive prostate cancer (mhspc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic hormone-sensitive prostate cancer (mhspc) treatment provided free

Apply for This Margate Location

Check if you qualify for this metastatic hormone-sensitive prostate cancer (mhspc) clinical trial in Margate, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Margate

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Margate site if eligible
  4. 4Begin participation

About This Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Study in Margate

The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Participant must be ≥ 18 at the time of signing the informed consent.
Histologically documented diagnosis of prostate adenocarcinoma that is de novo or recurrent and hormone-sensitive.
Metastatic disease confirmed prior to initiation of previous treatment with docetaxel or Lu-PSMA-containing regimens for mHSPC.
Previous treatment with docetaxel (IV, Q3w)- or Lu-PSMA (IV, Q6w) with last dose within past 6 months.
Participants must have the following:
Must be receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy.
Had no evidence of disease progression
Had all toxicities related to docetaxel- or Lu-PSMA-containing treatment (except for alopecia and peripheral neuropathy) resolved to CTCAE Grade 1 or lower.
PSA ≥ 0.2 ng/mL within 14 days prior to randomization.
Serum testosterone \< 1.7 nmol/L or 50 ng/dL.
Palliative radiotherapy for symptoms management will be permitted and is to be completed at least 4 weeks prior to randomization for wide field radiation therapy and at least 2 weeks prior to randomization for limited field radiation therapy.
Provision of a FFPE tumor tissue sample and a blood sample (for ctDNA).
Confirmed HRRm, HRD and PTEN status.
Adequate organ and bone marrow function.
Minimum life expectancy of 6 months.
Male, assigned at birth, inclusive of all gender identities.
Contraceptive use by participants or participant partners should be consistent with local regulations.
Capable of giving signed informed consent.

Exclusion Criteria

Hypersensitivity to saruparib, ARPI or any excipients of these products or any contraindication or restriction based on the local label.
Any history of persisting (\> 2 weeks) severe cytopenia due to any cause (eg, ANC\< 0.5 × 10\^9/L or platelets \< 50 × 10\^9/L)
Any known predisposition to bleeding (eg, active peptic ulceration, recent \[within6 months\] hemorrhagic stroke, proliferative diabetic retinopathy.
Spinal cord compression or brain metastases unless asymptomatic and stable.
History of MDS/AML or with features suggestive of MDS/AML
History of another primary malignancy, with some exceptions.
Any chronic gastrointestinal diseases or conditions including inability to swallow the formulated product that would preclude adequate absorption of any study drug.
History of seizure or predispose to seizure, including any history of loss of consciousness or transient ischemic attack within 12 months of enrolment.
Serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
Major surgical procedure or significant traumatic injury within 4 weeks of the first dose or an anticipated need for major surgery during the study.
Switched ARPI agent in previous treatment for mHSPC due to disease progression. Note: if the ARPI agent was switched due to any reason other than disease progression and switch was prior to ICF signature, participants will be eligible.
Any prior treatment with a PARPi or platinum chemotherapy.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Margate?

Yes, this clinical trial (NCT07711002) has an active research site in Margate, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treatment Options in Margate, FL

If you're searching for metastatic hormone-sensitive prostate cancer (mhspc) treatment options in Margate, FL, this clinical trial (NCT07711002) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Margate research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced metastatic hormone-sensitive prostate cancer (mhspc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic hormone-sensitive prostate cancer (mhspc) clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Margate, FL

See all prostate cancer clinical trials recruiting in Margate — not just this study.

Browse Prostate Cancer Trials in Margate →

Browse More Trials by Condition

Prostate Cancer TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsHidradenitis Suppurativa TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Margate?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Margate, FL